1096 The HOME INDUCTION Randomized Controlled Trial – Logistics for achieving delivery

The ARRIVE Trial has resulted in an increased demand for 39 week induction of labour (IOL) in normal-risk nulliparous patients, but this creates significant logistical challenges for already busy Labor Wards. A potential solution is commencing induction by means of outpatient cervical ripening at home (H-IOL), using vaginal prostaglandin (Propess/Cervidil) or osmotic cervical dilator (Dilapan-S). This secondary analysis evaluates the logistics of achieving vaginal delivery, including time taken and need for additional ripening modality.

Source: American Journal of Obstetrics and Gynecology - January 1, 2024 Category: OBGYN Authors: Sarah M. Nicholson, Orla Smith, Corina Oprescu, Eimear Wall, Sara El Nimr, Geraldine Gannon, Susan Hatt, Ita Shanahan, Bernard Kennedy, Ronan Daly, Claudia Looi, Elena Fernandez, Zara Molphy, Patrick Dicker, Karen Flood, Fergal D. Malone Source Type: research